Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell ... (HbF) in red blood cells ...

It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the first data ...

LONDON — People in England with sickle cell disease will now be able to access the world’s first CRISPR-based medicine under a pricing and reimbursement agreement reached between U.K. health ...

This switches to the adult form once they are born. Crucially foetal haemoglobin is not affected by sickle cell disease, so Crispr acts by dampening down the "switch" that makes the body produce ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

This switches to the adult form once they are born. Crucially foetal haemoglobin is not affected by sickle cell disease, so Crispr acts by dampening down the "switch" that makes the body produce the ...

A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled ... The treatment uses cutting-edge Crispr gene editing to remove blood from the patient, correct ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease ... to be licensed using gene-editing tool Crispr, which earned its inventors the ...